Angiotensin II type 2 receptor blockade increases bone mass
- PMID: 19004830
- PMCID: PMC2742875
- DOI: 10.1074/jbc.M807610200
Angiotensin II type 2 receptor blockade increases bone mass
Abstract
Renin angiotensin system (RAS) regulates circulating blood volume and blood pressure systemically, whereas RAS also plays a role in the local milieu. Previous in vitro studies suggested that RAS may be involved in the regulation of bone cells. However, it was not known whether molecules involved in RAS are present in bone in vivo. In this study, we examined the presence of RAS components in adult bone and the effects of angiotensin II type 2 (AT2) receptor blocker on bone mass. Immunohistochemistry revealed that AT2 receptor protein was expressed in both osteoblasts and osteoclasts. In addition, renin and angiotensin II-converting enzyme were expressed in bone cells in vivo. Treatment with AT2 receptor blocker significantly enhanced the levels of bone mass, and this effect was based on the enhancement of osteoblastic activity as well as the suppression of osteoclastic activity in vivo. These results indicate that RAS components are present in adult bone and that blockade of AT2 receptor results in alteration in bone mass.
Erratum for
- J Biol Chem. 284:4857.
Similar articles
-
Angiotensin II type-2 (AT2) receptor antagonism alters cardiovascular responses to static exercise and simultaneously changes glutamate/GABA levels within the ventrolateral medulla.Neurosci Res. 2009 Aug;64(4):372-9. doi: 10.1016/j.neures.2009.04.008. Epub 2009 Apr 18. Neurosci Res. 2009. PMID: 19379780
-
Effect of AT2 blockade on cardiac hypertrophy as induced by high dietary salt in the proatrial natriuretic peptide (ANP) gene-disrupted mouse.Can J Physiol Pharmacol. 2006 Jun;84(6):625-34. doi: 10.1139/y06-016. Can J Physiol Pharmacol. 2006. PMID: 16900247
-
Guanylyl cyclase-A inhibits angiotensin II type 2 receptor-mediated pro-hypertrophic signaling in the heart.Endocrinology. 2009 Aug;150(8):3759-65. doi: 10.1210/en.2008-1353. Epub 2009 Apr 16. Endocrinology. 2009. PMID: 19372206
-
[Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].Orv Hetil. 2003 Sep 7;144(36):1763-8. Orv Hetil. 2003. PMID: 14579673 Review. Hungarian.
-
Epochs in the depressor/pressor balance of the renin-angiotensin system.Clin Sci (Lond). 2016 May 1;130(10):761-71. doi: 10.1042/CS20150939. Clin Sci (Lond). 2016. PMID: 27128801 Review.
Cited by
-
The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?Cells. 2021 Mar 15;10(3):650. doi: 10.3390/cells10030650. Cells. 2021. PMID: 33804069 Free PMC article. Review.
-
Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes.J Bone Miner Metab. 2014 May;32(3):261-70. doi: 10.1007/s00774-013-0500-7. Epub 2013 Aug 10. J Bone Miner Metab. 2014. PMID: 23934056
-
Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass.PLoS One. 2014 May 8;9(5):e96323. doi: 10.1371/journal.pone.0096323. eCollection 2014. PLoS One. 2014. PMID: 24810249 Free PMC article.
-
The interplay between bone and heart health as reflected in medication effects: A narrative review.Womens Health (Lond). 2023 Jan-Dec;19:17455057231165549. doi: 10.1177/17455057231165549. Womens Health (Lond). 2023. PMID: 37078403 Free PMC article. Review.
-
Telmisartan Prevents Alveolar Bone Loss by Decreasing the Expression of Osteoclasts Markers in Hypertensive Rats With Periodontal Disease.Front Pharmacol. 2020 Nov 11;11:579926. doi: 10.3389/fphar.2020.579926. eCollection 2020. Front Pharmacol. 2020. PMID: 33364953 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases